The Board of the Company at its meeting held today has approved the transfer of the Company''s Nebulizer brands/ IP portfolio to Glenmark Healthcare Limited, a wholly owned subsidiary.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals' Board has approved the transfer of its Nebulizer brands and IP portfolio to Glenmark Healthcare Limited (GHL), a wholly owned subsidiary. The transaction is valued at Rs. 223 crore in cash, based on an independent valuer's report. For the nine months ended December 2025, the Nebulizer business generated revenue of Rs. 71.6 crore, accounting for approximately 1.3% of the company's standalone revenue. GHL had a negative net worth of Rs. 9.9 crore as of March 2026. The agreement was entered on 1st June 2026 and is expected to complete by 30th June 2026. The company says this will enable sharper strategic focus, greater operational agility, and allow GHL to set up a dedicated Nebulizers manufacturing facility. The transaction is classified as a related party transaction but has been conducted at arm's length. There is no change in Glenmark's shareholding pattern.
This is an internal restructuring within the Glenmark group — transferring an under-1.3% revenue business to a wholly owned subsidiary at fair value. No change in shareholding or public float, so minimal direct impact on Glenmark's stock in the near term.